FOI Request
- Disclosure ID
- FOI/03516
- Request Date
- January 16, 2020
- Subject
- Colorectal Cancer Treatments
- Description
1). Within your health trust how many patients have been treated in the past 6 months with the following agent for colorectal cancer [CRC];
Aflibercept
Bevacizumab
Capecitabine
CAPIRI
CAPOX
Cetuximab not in combination with FOLFIRI or FOLFOX
Cetuximab in combination with FOLFIRI
Cetuximab in combination with FOLFOX
Irinotecan
FOLFIRI
FOLFOX
Oxaliplatin
Panitumumab not in combination with FOLFIRI or FOLFOX
Panitumumab in combination with FOLFIRI
Panitumumab in combination with FOLFOX
Nivolumab
Raltitrexed
Ramucirumab
Regorafenib
Sorafenib
5FU only
Tegafur Uracil + 5FU
Trifluridine–tipiracil
XELOX
Other
2). Within your health trust how many patients have been treated in the past 6 months with the following agent for Renal Cell Carcinoma :
Sunitinib
Avelumab + Axitinib
Axinitib
Cabozantinib
Everolimus
Lenvantinib + Everolimus
Nivolumab
Nivolumab + Ipilimumab
Pazopanib
Pembrolizumab + Axitinib
Sunitinib
Temsirolimus
Tivozanib
3). Does your health trust participate in any ongoing clinical trials for the treatment of renal cell cancer patients, if so how many patients are currently taking part in clinical trials / what is the name/s of the trials?
- Response
1). Please see the accompanying document and note we only hold information from the 7th of October onwards due to the implementation of a new system.
2). Please see the accompanying document and note we only hold information from the 7th of October onwards due to the implementation of a new system.
3). I can confirm our Trust is currently not participating in any clinical trials for the treatment of renal cell cancer patients.